Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper 利用 QSP 优化免疫肿瘤药物发现与开发 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…Certara2019 年 6 月 19 日
7 Things to Know About the China Pharmaceutical Industry Blog 7 Things to Know About the China Pharmaceutical Industry China is the second largest pharmaceutical market in the world. Demand is likely to increase…Certara2018 年 10 月 16 日
Pharmacokinetic/ Toxicokinetic Services Brochure Pharmacokinetic/ Toxicokinetic Services As your partner for drug development and regulatory strategy, Certara has expanded its services to…Certara2018 年 5 月 18 日
Changing the Game in Drug Development Brochure 改变药物开发的局面 At Certara, we are innovators, dedicated to helping our clients develop new therapies and target…Certara2018 年 3 月 19 日
Rare Disease and Orphan Drug Development Brochure 罕见病和孤儿药开发 There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…Certara2016 年 8 月 3 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Publication More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…Certara2016 年 7 月 1 日
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data Publication Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…Certara2016 年 6 月 1 日
Metformin and Cimetidine: Physiologically-based Pharmacokinetic Modeling to Investigate Transporter Mediated Drug–drug Interactions Publication Metformin and Cimetidine: Physiologically-based Pharmacokinetic Modeling to Investigate Transporter Mediated Drug–drug Interactions Certara2016 年 6 月 1 日
Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates with Estron e-3-Sulfate Transport in Caco-2 Publication Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates with Estron e-3-Sulfate Transport in Caco-2 Transporter mRNA and protein expression data are used to extrapolate in vitro transporter kinetics to in…Certara2016 年 4 月 1 日
In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part I—A Cross-laboratory Comparison of Transporter-protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells Publication In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part I—A Cross-laboratory Comparison of Transporter-protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells Over the last 5 years the quantification of transporter-protein absolute abundances has dramatically increased in parallel to the expanded…Certara2016 年 3 月 1 日